medigraphic.com
Colegio de Medicina Interna de México.

2014, Number 1

<< Back Next >>

Med Int Mex 2014; 30 (1)

Correlation between Fibrinogen Levels and Glycated Hemoglobin in Patients with Diabetes Mellitus Type 2

Pedro-González A, Huerta- Ramírez S, Cerda-Téllez F, Geuguer- Chávez L, López-Vejar CE

Language: Spanish
References: 38
Page: 24-31
PDF size: 641.67 Kb.


ABSTRACT

Background: It has been reported a pathophysiological relationship between fibrinogen and atherosclerosis, thrombosis, inflammation, and coronary events, as well as between better glycemic control and fewer complications.
Objective: To determine whether there is a correlation between the concentrations of fibrinogen and glycosylated hemoglobin in diabetic patients.
Material and method: A transversal analytical study was done with data from 29 patients. Pearson correlation was performed for glycosylated hemoglobin (HbA1c) and fibrinogen, for qualitative variables U Mann-Whitney and Fisher's exact tests were used. STATA version 11 was used.
Results: Of the 29 patients analyzed, we found a mean glucose of 186.9 ± 62.7 mg/dL, mean HbA1c of 9.69 ± 2.8%, and mean fibrinogen of 445.6 ± 106 mg/dL. A correlation between HbA1c and fibrinogen was found (r = 0.24, p = 0.19). Patients with diabetic retinopathy had a mean fibrinogen of 521 ± 78 mg/dL and patients without retinopathy had a mean fibrinogen of 425 ± 104 mg/dL (p = .03).
Conclusion: No significant correlation was found between fibrinogen and HbA1c. High fibrinogen levels are significantly associated with diabetic retinopathy.


REFERENCES

  1. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 2013;36.

  2. Pirat J. Diabetes mellitus and its degenerative complications. Diabetes Care 1978;1:168-188.

  3. The DCCT Research Group. Diabetes control and complications trial (DCCT): Results of feasibility study. Diabetes Care 1987;10.

  4. American Diabetes Association. Implications of the United Kingdom prospective diabetes study. Diabetes Care 2002;25.

  5. Secretaría de Salud. Programa de acción: diabetes mellitus. Primera edición. México 2001.

  6. Norma Oficial Mexicana NOM-015-SSA2-2010 para la prevención, tratamiento y control de la diabetes mellitus.

  7. Barbara Thorand, et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 2006;26:398-405.

  8. Peter Gæde, MD, y col. Intensified, multiple risk factor intervention in patients with type 2 diabetes at high risk cuts cardiovascular events by half. N Engl J Med 2008;358:580- 591.

  9. World Health Organization. Prevention of diabetes mellitus. Report of a WHO Study Group. Geneva: World Health Organization 1994;844.

  10. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición 2012. Resultados nacionales. Primera edición. México 2012.

  11. INEGI. Consulta interactiva de datos, defunciones generales, causas detalladas CIE y lista mexicana de enfermedades.

  12. Ávalos García MI, y col. Control metabólico en el paciente con diabetes mellitus tipo 2 en el municipio de Centla, Tabasco, México. Salud en Tabasco 2007;13.

  13. Pérez CL y col. Fibrinógeno, dislipidemias, fibrinólisis y actividad lipolítica en pacientes diabéticos tipo 2. Relación con la obesidad. Revista Cubana de Angiología y Cirugía Vascular 2004;5.

  14. Federación Mundial del Corazón. World hearth day. A workplace that encourages healthy habits can reduce heart disease and stroke 2009.

  15. Paterno CA. Los enigmas del fibrinógeno (y la enfermedad coronaria). Rev Fed Arg Cardiol 2000;29:515-517.

  16. Sistema Nacional de Información en Salud [SINAIS] (2009). Cubos dinámicos de egresos hospitalarios. Revisado el 7 de agosto de 2009. Disponible en: http://www.sinais.salud. gob.mx/basesdedatos/index.html

  17. Sanne G. Swinnen MD, et al. Insulin therapy for type 2 diabetes. Diabetes Care, 2009;32: 253-259..

  18. Cairo Toledano J y col. Determinantes de adherencia terapéutica y control metabólico en pacientes ambulatorios con diabetes mellitus tipo 2. Revista Mexicana de Ciencias Farmacéuticas 2008;39:9-17.

  19. González Hita M y col. Obesidad y diabetes mellitus tipo 2. Redalyc 2001;3:54-60.

  20. Flores Ramírez J, Aguilar Rebolledo F. Diabetes mellitus y sus complicaciones. La epidemiología, las manifestaciones clínicas de la diabetes tipo 1 y 2. Diabetes gestacional, Plasticidad & Restauración Neurológica 2006;5:139-151.

  21. Meco JF, Pintó X. Cálculo del riesgo cardiovascular. Clin Invest Arterioscl 2002;14:198-208.

  22. Grupo de trabajo de diabetes mellitus y enfermedad cardiovascular de la Sociedad Española de Diabetes (SED). Diabetes mellitus y enfermedad cardiovascular. 1a edición, España, Mayo Ediciones, 2007.

  23. Rabbani LE, Loscalzo J. Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atherosclerosis 1994;105:1-7.

  24. Canseco Ávila LM y col. Fibrinógeno, ¿factor o indicador de riesgo cardiovascular? Arch Cardiol Méx 2006;76:158-172.

  25. Scarabin PY, Aillaud MF, Amouyel P, Evans A, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10500 male participants in a prospective study of myocardial infarction. The PRIME study. Thromb Haemost 1998;80:749-756.

  26. Folson AR, Peacock JM, Nieto FJ, Rosamond WD, et al. Plasma fibrinogen and incident hypertension in the atherosclerosis risk in communities (ARIC) study. J Hypertens 1998;16:1579-1583.

  27. Meade TW, North WR, Chakrabarti R, Stirling Y, et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980;1:1050-1054.

  28. Stone MC, Thorp JM. Plasma fibrinogen a major coronary risk factor. J R Coll Gen Pract 1985;35:565-569.

  29. Baker IA, Sweetnam PM, Yarnell JW, Bainton D, et al. Haemostatic and other risk factors for ischaemic heart disease and social class: evidence from the Caerphilly and Speedwell studies. Int J Epidemiol 1988;17:759-765.

  30. Kannel B, Wolf PA, Castelli WP, D’agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA 1987;258:1183-1186.

  31. Balleisen L, Bailey J, Epping PH, Schulte H, et al. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985;54:475-479.

  32. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-963.

  33. Becker RC, Cannon CP, Bovill EG, Tracy RP, et al. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial). Am J Cardiol 1996;78:142-147.

  34. Lindahl B, Toss H, Siegbahn A, Venge P, et al, for The FRISC study group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139- 1147.

  35. Nikolaos Papageorgiou. Is fibrinogen a marker of inflammation in coronary artery disease? Hellenic J Cardiol 2010;51:1-9.

  36. US Department of Health and Human Services. National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressucre Education Program, The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. NIH Publication No. 04-5230, 2004.

  37. Aguilar-Barojas S. Fórmulas para el cálculo de la muestra en investigaciones de salud. Salud en Tabasco 2005;11.

  38. Pértegas Díaz y col. Determinación del tamaño muestral para calcular la significación del coeficiente de correlación lineal. Unidad de Epidemiología Clínica y Bioestadística. Complexo Hospitalario Juan Canalejo. A Coruña: Cad Aten Primaria 2002;9:209-211.




2020     |     www.medigraphic.com